AHR and cancer: Importantly, this has allowed us to answer the long-standing question about the degradation of transcriptionally active AHR and PARP7, both of which are important therapeutic targets in cancer, infections, and immune diseases (Gorelik et al, 2025; Polonio et al, 2025).